Landon Whitby
Director, Chemical Biology & Proteomics Light Horse Therapeutics
Landon Whitby is Director of Chemical Biology & Proteomics at Light Horse Therapeutics, where he leads the optimization of platform technologies, as well as the application of MS-based proteomics techniques in small molecule discovery and protein interactomics. He completed his PhD in the Cravatt Lab at the Scripps Institute.
Seminars
Wednesday 4th February 2026
Optimizing Scalable Proteomics Techniques for Efficient Target Deconvolution & Small Molecule Drug Discovery
9:00 am
- Developing workflows to enable high throughput chemoproteomic analysis with enhanced efficiency
- Strategically optimizing sensitivity, coverage, and throughput to detect a full range of proteins, including those in low abundance
- Evidence to show how proteomics accelerates drug discovery and unlocks previously inaccessible targets
